Fusobacterium nucleatum Promotes Cisplatin-Resistance and Migration of Oral Squamous Carcinoma Cells by Up-Regulating Wnt5a-Mediated NFATc3 Expression.


Journal

The Tohoku journal of experimental medicine
ISSN: 1349-3329
Titre abrégé: Tohoku J Exp Med
Pays: Japan
ID NLM: 0417355

Informations de publication

Date de publication:
04 2021
Historique:
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 16 11 2021
Statut: ppublish

Résumé

Bacterial infection contributes to tumor development and malignant progression. Fusobacterium nucleatum (F. nucleatum) is reported to promote oral squamous cell carcinoma. However, molecular bases of F. nucleatum regulating oral cancer cells have not been fully elucidated. We report here that F. nucleatum down-regulates p53 and E-cadherin via the Wnt/NFAT pathway to promote cisplatin-resistance and migration in oral squamous carcinoma cells. We pretreated Cal-27 and HSC-3 cells with F. nucleatum and the survival rates against cysplatin (Cis-diamminedichloroplatinum, CDDP) were significantly higher in treated cells. The expressions of migration and apoptosis-related proteins like E-cadherin and p53 were lower in western blot analysis. We observed that F. nucleatum was an activator of the Wnt/NFAT pathway. The expression levels of the Wnt pathway gene wnt5a and Nuclear factors of activated T cells 3 (NFATc3) were notably higher in treated cells. With the inhibition effect of NFAT-inhibitory peptide VIVIT, the expressions of E-cadherin and p53 in response to F. nucleatum infection were up-regulated reversely. We concluded that F. nucleatum might promote cisplatin-resistance and migration of oral squamous cell carcinoma cells through the Wnt/NFAT pathway.

Identifiants

pubmed: 33840648
doi: 10.1620/tjem.253.249
doi:

Substances chimiques

NFATC Transcription Factors 0
NFATC3 protein, human 0
Oligopeptides 0
VIVIT peptide 0
WNT5A protein, human 0
Wnt-5a Protein 0
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-259

Auteurs

Jingshu Da (J)

Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University.

Xiaoqian Wang (X)

Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University.
Department of Periodontology, Affiliated Stomatological Hospital of Nanjing Medical University.

Lu Li (L)

Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University.
Department of Periodontology, Affiliated Stomatological Hospital of Nanjing Medical University.

Yan Xu (Y)

Jiangsu Key Laboratory of Oral Disease, Nanjing Medical University.
Department of Periodontology, Affiliated Stomatological Hospital of Nanjing Medical University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH